Literature review · Tissue recovery / Immune & inflammation

LL-37

LL-37 has been investigated as a topical wound-healing drug. The selected phase IIb trial did not show a significant benefit across the overall study population, despite exploratory subgroup signals.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The overall trial result is the primary interpretive anchor. Post-hoc findings in participants with larger ulcers can generate hypotheses, but do not turn a negative overall trial into established efficacy.

Identity & scope

The research concerns LL-37, a host-defence peptide. A pharmaceutical topical preparation used alongside compression therapy is different from a catalogue vial or nasal format.

Catalogue labels covered: LL-37.

What the research shows

  • Mahlapuu and colleagues studied a defined topical preparation in hard-to-heal venous leg ulcers.
  • No significant overall healing improvement was detected; some larger-ulcer subgroup findings were exploratory.

Critical interpretation

Early signals need later confirmation

The earlier trial was useful for exploring a response pattern and informing a subsequent experiment. Its size and several treatment groups make a precise general efficacy estimate difficult. The later overall null result therefore belongs beside the early signal, not behind it. Our interpretation is that this sequence shows the value of follow-up trials: a plausible and initially encouraging candidate still needs confirmation on defined clinical outcomes. [2] [1]

A subgroup finding is a new question

A larger-ulcer signal can be biologically interesting without being a proven treatment effect. When subgroups and several correlated wound measures are examined, their statistical dependence and the number of comparisons matter. The most informative next trial would define the subgroup, endpoint and analysis before enrolment, rather than choose them after an overall negative result. [1]

Keep the endpoint and care setting attached

A healing rate, area reduction and sustained complete closure are different outcomes. Their clinical importance should be evaluated with time, uncertainty and concurrent standard care visible. The selected topical trials also cannot answer whether systemic host-defence signalling would improve unrelated infections. The research programme and its formulation should remain the unit of interpretation. [2] [1]

Limitations & uncertainties

  • The study concerns venous leg ulcers with concurrent standard compression care.
  • Post-hoc subgroup analyses need prospective confirmation and careful attention to multiple comparisons.
  • The trial does not establish systemic antimicrobial, immune-enhancing or nasal effects, or verify a HeartPep batch.

Open research questions

  • Can a prospective trial reproduce the proposed subgroup effect?
  • Which formulation and wound context, if any, yield a reproducible clinical benefit?

Selected papers & source records

Download bibliography
Human studyNamed compoundFull text consulted

1. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial (opens in a new tab)

Mahlapuu M, Sidorowicz A, Mikosinski J, et al. (2021). Wound Repair and Regeneration. DOI: 10.1111/wrr.12977 (opens in a new tab) · PMID 34687253

Design & population
Phase IIb double-blind randomised placebo-controlled topical trial, with 148 treated patients receiving compression therapy.
What the study found
No significant healing improvement in the overall population. Post-hoc analyses suggested effects in some patients with larger ulcers.
Limits on interpretation
Selected subgroup results were not a substitute for the overall result. The studied topical drug does not validate other delivery formats.
Human studyNamed compoundAbstract / record checked

2. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (opens in a new tab)

Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O (2014). Wound Repair and Regeneration. DOI: 10.1111/wrr.12211 (opens in a new tab) · PMID 25041740

Design & population
First-in-human trial with 34 participants, a randomised double-blind treatment phase and follow-up after a placebo run-in.
What the study found
Reported healing-predictor signals at lower studied topical concentrations; the highest concentration did not differ from placebo.
Limits on interpretation
Small multi-group early trial. The result is not equivalent to confirmed complete-healing efficacy or long-term clinical safety.

Search & review scope

Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.

Early topical trial and later phase IIb trial. Later full-text endpoints, subgroup methods and participant flow consulted; no claim of comprehensive wound-literature coverage.

Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.

Recorded search terms
  • Direct review of existing reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC9298190/
  • LL37 first human venous leg ulcer trial 2014 randomized 2014 Gronberg
  • "10.1111/wrr.12977" correction retraction

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. LL-37: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ll-37.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes